Up­start can­cer biotech re­cruits a top Pfiz­er on­col­o­gy re­searcher as CSO — could an IPO be far be­hind?

As Vi­vid­ion ex­ecs proud­ly showed off an $82 mil­lion B round last spring, the start­up was ea­ger to dis­cuss 3 pre­clin­i­cal pro­grams —an adap­tor pro­tein, a tran­scrip­tion fac­tor and an E3 lig­ase — that were an­gling to­ward proof-of-con­cept da­ta. Now they have found a high-pro­file ear­ly-stage phar­ma ex­ec to guide them to the promised land of clin­i­cal de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER